ORGO (Organogenesis Holdings) Total Liabilities: $138.6 Mil (As of Mar. 2026)

What is Organogenesis Holdings Total Liabilities?

Organogenesis Holdings ORGO -3.08% 67 Total Liabilities is $138.6 Mil as of Mar. 2026. GuruFocus rates ORGO with a GF Score™ of 67/100 and a GF Value™ of $3.10 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Organogenesis Holdings's Total Liabilities for the quarter that ended in Mar. 2026 was $138.6 Mil.

Organogenesis Holdings's quarterly Total Liabilities increased from Sep. 2025 ($123.85 Mil) to Dec. 2025 ($164.81 Mil) but then declined from Dec. 2025 ($164.81 Mil) to Mar. 2026 ($138.65 Mil).

Organogenesis Holdings's annual Total Liabilities declined from Dec. 2023 ($181.36 Mil) to Dec. 2024 ($112.57 Mil) but then increased from Dec. 2024 ($112.57 Mil) to Dec. 2025 ($164.81 Mil).

Organogenesis Holdings Total Liabilities Related Terms

Organogenesis Holdings Total Liabilities Historical Data

* Premium members only.

The historical data trend for Organogenesis Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organogenesis Holdings Total Liabilities Chart

Organogenesis Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

201.92

183.69

181.36

112.57

164.81

Organogenesis Holdings Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															99.33	99.91	123.85	164.81	138.65

67GF Score

Organogenesis Holdings Inc ORGO

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Organogenesis Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Organogenesis Holdings's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	100.124	+	(63.495	+	1.193
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	164.8

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	598.73	-	433.918
	=	164.8

Organogenesis Holdings's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	76.021	+	(61.138	+	1.486
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	138.6

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	519.992	-	381.347
	=	138.6

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $138.6 Mil mean?

Organogenesis Holdings (ORGO) has a Total Liabilities of $138.6 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Organogenesis Holdings and its competitors.

Is Organogenesis Holdings' Total Liabilities too high?

Organogenesis Holdings' current Total Liabilities is $138.6 Mil. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Organogenesis Holdings' Total Liabilities compare to TKNO and AKBA?

Organogenesis Holdings' Total Liabilities of $138.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Drug Manufacturers company?

A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Organogenesis Holdings and its competitors. Organogenesis Holdings's current Total Liabilities is $138.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Organogenesis Holdings stock overvalued right now?

Based on GuruFocus' analysis, Organogenesis Holdings (ORGO) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.10, compared to a current price of $2.36 — trading 23.9% below its estimated fair value. The current Total Liabilities is $138.6 Mil. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Organogenesis Holdings (ORGO), the current Total Liabilities is $138.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organogenesis Holdings (ORGO) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of $2.36 is trading 23.9% below its estimated GF Value™ of $3.10. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for ORGO:

Total Liabilities: $138.6 Mil
GF Value™: $3.10 vs. price of $2.36 (23.9% below fair value)
GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the ORGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organogenesis Holdings Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TKNO AKBA SIGA ELTP ANIK LFCR EBS DERM NIKA EOLS XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges 2PQ:Germany

Address 85 Dan Road, Canton, MA, USA, 02021

Website https://www.organogenesis.com

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

67GF Score

Get the complete analysis for ORGO

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.36

Price

$3.10

GF Value

View ORGO Analysis

See Total Liabilities data for all stocks →